Page 22 - Stephen Schultz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. COMPASS Pathways announces pricing of public offering COMPASS Pathfinder Ltd.April 30, 2021 GMT     London, UK, 30 April 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares at a public offering price of $36.00 per AD...

COMPASS Pathfinder Ltd.: COMPASS Pathways announces pricing of public offering London, UK, 30 April 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares ("ADSs") representing 4,000,000 ordinary shares at a public offering price of $36.00 per ADS for total gross proceeds of $144.0 million. All ADSs sold in the offering were offered by COMPASS. The offering is expected ...

COMPASS Pathways launches proposed public offering COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares each representing one ordinary share. Each of the ADSs is being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 … COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to e...

(0) Study concludes that psilocybin findings should be explored further in larger studies London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASS's COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a sel...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. New England Journal of Medicine publishes exploratory study showing signals of positive ... COMPASS Pathfinder Ltd.April 15, 2021 GMT London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the  New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin com...